Coronary CT Angiography as the Primary Initial Method of Evaluating Patients With Subacute Chest Pain (CT PRIME)

Withdrawn

• Conditions: Coronary Artery Disease

• Registration Number: NCT00584337
• Lead Sponsor: William Beaumont Hospitals

Brief Summary

This study is designed to evaluate a new approach to the diagnosis of chronic or sub-acute chest pain patients in the out-patient setting. Patients in this study are selected to be "low-risk", meaning they are not having an acute or recent heart attack (AMI), based on screening blood tests and electrocardiograms (EKGs). In addition, these patients have a low or intermediate pre-test likelihood of the coronary artery disease (CAD), which means that probability of the CAD based on the available clinical and historical information, does not make a diagnosis of the CAD a certain clinical diagnosis in the particular patient and this, in turn, requires an additional diagnostic work up.

Detailed Description

To compare and contrast the diagnostic efficacy of coronary CT angiography (CCTA) to standard of care-myocardial perfusion imaging (MPI) as an initial diagnostic test for evaluation of patients with suspected angina pectoris and no known CAD.

Study Timeline

• Study First Submitted: 2007-12-20
• Study First Submitted QC: 2007-12-31
• Study Start: 2008-01
• Study First Posted: 2008-01-02
• Primary Completion: 2009-06
• Study Completion: 2010-06
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-13
• Last Update Posted: 2016-06-15

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Non-acute (onset≥72 hours) chest pain suggestive of possible underlying CAD in out-patient.
2. Low or low-to-intermediate clinical likelihood of the CAD.
3. Very low or low risk Goldman-Reilly risk group.
4. Ability to provide informed consent.
5. Age equal to or greater than 18 years.

Exclusion Criteria

1. Intermediate or higher risk of ACS by Goldman-Reilly criteria:

   1. Electrographic evidence of acute ST elevation myocardial infarction (STEMI) with ST segment elevation equal to or greater than 1mm in two or more contiguous leads).
   2. Electrocardiographic evidence of acute non-ST infarction (NSTEMI) or acute myocardial ischemia, including flat to down sloping ST segment depression equal to or greater than 1mm and/or T wave inversion equal to or greater than 2mm in 2 or more leads.
   3. Positive cardiac biomarkers (troponin and/or creatinine phosphokinase MB fraction) compatible with acute myocardial infarction on initial laboratory testing, based on the local laboratory upper range of normal.
   4. Clinical instability including cardiogenic shock, hypotension (systolic blood pressure < 90 mmHg), refractory hypertension (systolic blood pressure > 180 mmHg on therapy), sustained ventricular or atrial arrhythmia requiring intravenous medications.

2. Presence of known pre-existing coronary artery disease (known prior myocardial infarction, EKG evidence compatible with prior infarction, prior angiographic evidence of significant coronary artery disease, history of prior coronary revascularization).

3. Presence of signs or symptoms compatible with obvious non-cardiac chest pain, including musculoskeletal, gastrointestinal or neuropathic causes.

4. Renal insufficiency (creatinine >1.5) or history of chronic or transient renal failure.

5. Atrial fibrillation or other markedly irregular rhythm.

6. Pregnancy or unknown pregnancy status.

7. Known allergy to iodinated contrast.

8. Inability to tolerate beta-blocking drugs, including patients with reactive airways disease requiring maintenance inhaled bronchodilators or steroids, complete heart block or second-degree atrioventricular block.

9. Iodinated contrast administration within the past 48 hours.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome variable: diagnostic efficiency.	6 months, 1 year

Secondary Outcome Measures

Name	Time	Method
Secondary outcome variables: diagnostic accuracy, prognostic accuracy.	6 months, 1 year

Trial Locations

Locations (1)

William Beaumont Hospital; 🇺🇸 Royal Oak, Michigan, United States